Tokyo, April 6 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061125) titled 'Treatment of Advanced Ovarian and Fallopian Tube Cancer Using Integrated Genomic Diagnostics via Ultrasound-Guided Fine-Needle Biopsy' on April 6.
Study Type:
Observational
Primary Sponsor:
Institute - Kagoshima University
Condition:
Condition - Advanced ovarian and fallopian tube cancer
Classification by malignancy - Malignancy
Genomic information - YES
Objective:
Narrative objectives1 - The objective is to establish a system for selecting first-line therapy based on integrated analysis using genomic panel testing in ovarian cancer, using ultrasound-guided needle biopsy.
Basic objectives2 - Safety,Efficacy
Eligibility:
Age-lower limit - 20
years-old
=
Gender - Female
Key inclusion criteria - Patients currently receiving outpatient care at Kagoshima University Hospital who are 20 years of age or older and capable of providing informed consent, and who are suspected of having ovarian or fallopian tube cancer
Key exclusion criteria - Other than the above
Target Size - 50
Recruitment Status:
Recruitment status - Open public recruiting
Date of protocol fixation - 2023 Year 12 Month 19 Day
Date of IRB - 2023 Year 12 Month 19 Day
Anticipated trial start date - 2023 Year 12 Month 20 Day
Last follow-up date - 2032 Year 03 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069938
Disclaimer: Curated by HT Syndication.
